Hot Pet Therapeutic Antibody Targets
The landscape of companion animal healthcare is rapidly evolving, with monoclonal antibodies emerging as powerful tools to address cancer, immune-mediated conditions, inflammatory disorders, and infectious diseases. At Creative Biolabs, we provide cutting-edge CRO solutions to accelerate the development of therapeutic antibodies against some of the most impactful targets in veterinary medicine.
Hot Pet Antibody Targets
We offer discovery and development support for a wide spectrum of promising veterinary targets, including but not limited to:
|
Oncology & Immune Checkpoints Immuno-oncology approaches, especially checkpoint inhibitors and anti-growth factor antibodies, are gaining traction in canine osteosarcoma, lymphoma, and mast cell tumors. |
||||
|---|---|---|---|---|
| VEGF | TNF-α | TGF-β | SIRPα/CD47 Axis | PD-1/PD-L1 |
| CTLA-4 | CD276 | CD33 | CD25 | CD20 |
| CD123 | CCR4 | Canine CD3/TCR | CXCR4 | CD3L1 (ITPRIPL1) |
|
Autoimmune & Inflammatory Disorders Chronic inflammation and immune dysregulation contribute to debilitating conditions in pets. Monoclonal antibodies can selectively block or enhance immune pathways, offering safer alternatives to broad immunosuppressants. |
||||
|---|---|---|---|---|
| IL-6 | IL-5/IL-5R | IL-4 | IL-31 | IL-23 |
| IL-17 | IL-13 | IL-10 | IFN-γ | ICOS/ICOS-L |
| GM-CSF | JAK1 | RANKL | CD52 | BAFF / APRIL |
|
Pain & Neurology Chronic pain, particularly due to osteoarthritis, is a major challenge in older dogs. Traditional treatments such as NSAIDs may be insufficient or cause side effects, driving demand for safer biologics. |
||||
|---|---|---|---|---|
| NGF | ||||
|
Infectious Disease Infectious diseases remain a serious threat to companion animals, especially in global markets. Antibody therapeutics can neutralize pathogens, block entry, or enhance immune clearance. |
||||
|---|---|---|---|---|
| Canine Parvovirus | Canine Distemper Virus | |||
Why Focus on These Targets?
Our Expertise: From Concept to Candidate
Our discovery platforms are tailored to generate high-affinity, species-optimized antibodies for veterinary use. With strong R&D capabilities and a focus on translational relevance, we help our partners move rapidly from early research to preclinical validation.
- Species-Specific Antibody Discovery: Optimized for canine and feline immune systems.
- Lead Optimization: We offer services including antibody caninization, felinization, affinity maturation and developability assessments.
- Comprehensive Validation: In vitro and ex vivo functional studies and in vivo model development.
- Flexible Collaboration: Customized workflows aligned to your therapeutic goals.
Fig 1. NGF plans a role in pain perception and nervous system plasticity in osteoarthritis. 1
Partner with Creative Biolabs
With growing demand for innovative therapeutics in veterinary medicine, the time to act is now. Creative Biolabs' expertise in antibody discovery and development empowers your pipeline to advance quickly, efficiently, and with confidence.
Looking to explore antibody discovery against one of these hot veterinary targets? Drop us your indication or target hypothesis, and we'll show how the CynoCure™ and FeliCure™ platforms can accelerate your path to a lead candidate.
Reference
- Wang, Jianzhong et al. "Current Review of Monoclonal Antibody Therapeutics in Small Animal Medicine." Animals : an open access journal from MDPI vol. 15,4 472. 7 Feb. 2025. 2. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ani15040472